Novartis said it is pushing ahead with a late-stage study of its experimental drug ligelizumab after announcing the medicine outperformed Roche's Xolair in a Phase II clinical trial against urticaria, also known as hives.
from Reuters: Money News https://ift.tt/2RxT7pl
via
IFTTT
0 comments: